Phase 1 N=4 Pancreatic Islet Cell Transplantation
Type 1 Diabetes
Primary: Achievement of Insulin Independence at 12-month Post Transplant — 1 participant
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=67 Metabolic Syndrome in PCOS: Precursors and Interventions
Polycystic Ovary Syndrome · Metabolic Syndrome
Primary: Change in Low-density Lipoprotein (LDL) Levels Over the Study Period — -6; -9; -7 mg/dL
Phase 3 N=201 An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia
Schizophrenia
Primary: Double Blind (DB) Phase: Median Time to Relapse — NA; 49.0 Days
Phase 4 N=118 Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty
Knee Replacement Surgery · Osteoarthritis
Primary: Change in Hemoglobin (Hgb) Level at Day 2 Post-operatively — -3.73; -3.70 g/dL — p=0.453
Phase 3 N=44 Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
Fabry Disease
Primary: Change From Baseline to Month 12 in Left Ventricular Mass Indexed to Height (LVMI) — 3.2; 0.5; -10.3 g/m^2.7
Phase 4 N=23 Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery
Insulin Sensitivity
Primary: Change in Insulin Sensitivity — 3.2; 2.4 mg/(kg min)
N/A N=50 Study of Clinical Performance of Corneal Topography Measurement Using an Optical Biometer
Corneal Topography
Primary: In-vivo Repeatability of Corneal Topography Measurements With Lenstar LS 900 Topography: Sample Mean of Differences of Mean Power and Sample Mean of Std. Dev of Local…
Phase 2 N=377 CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis
Multiple Myeloma and Plasma Cell Neoplasm
Primary: The Number of Confirmed Hematologic Responses (Complete, Partial, or Very Good Partial Response) — 39; 11; 9; 10 participants
Phase 1 N=42 Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults
Pneumococcal Vaccines
Primary: Unsolicited Adverse Event Reports — 7; 6; 5; 6 participants
Phase 2 N=22 Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Breast Cancer · Breast Tumors · Neoplasms, Breast
Primary: Objective Response Rate (ORR) — 1 participants
Phase 3 N=529 A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Malignant Melanoma
Primary: Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines — 4.8; 2.5…
Phase 2 N=75 Safety of Urate Elevation in Parkinson's Disease
Parkinson Disease
Primary: Tolerability — 96; 96; 100 percentage of participants
Phase 3 N=904 Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease I
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at 24 Weeks — -0.009; 0.142; 0.156; 0.168 Liter — p=<0.0001
Phase 3 N=31 Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
Gaucher Disease
Primary: Hemoglobin — 13.5; 13.3; 13.3; 13.4 g/dL
N/A N=8 Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)
Pregnancy · Neonates
Primary: Percentage of Mothers With ≥1 Live Born Infant During Follow-up (Take-Home Baby Rate): Protocol Defined — 0.0; 33.3 percentage of participants